Replimune Group (REPL) Nosedives 39% as FDA Approval ... - Finviz
Stock screener for investors and traders, financial visualizations.
finviz.comHere’s a concise update on Replimune (ticker: REPL) as of the latest public coverage.
-
Recent FDA interaction and status: Replimune reported that the FDA issued a Complete Response Letter (CRL) regarding the RP1 BLA for advanced melanoma, with regulatory feedback that has led the company to reassess pathways including accelerated approval and manufacturing plans. This CRL prompted management to outline potential impacts on operations and funding needs. This is the central recent regulatory milestone that has driven investor sentiment and operational planning. [Source coverage referencing the CRL and FDA dialogue in April 2026]
-
Clinical and data updates: Replimune presented updates on RP1 plus nivolumab, including biomarker analyses from the IGNYTE program and data suggesting RP1 may modulate mechanisms of resistance to PD-1 blockade; these updates were highlighted at SITC 2025 and related conferences. These data points are part of the company’s ongoing efforts to demonstrate potential activity and define a path forward. [Source coverage of SITC 2025 data]
-
Market reaction: Following the CRL news and related FDA feedback, there was notable trading activity and coverage noting a decline in REPL shares as investors weighed the regulatory hurdles and the potential need for alternative development pathways. [Source summaries noting stock reaction]
-
Additional program context: Beyond RP1, Replimune has ongoing exploration of RP2 and RP3 to expand the platform’s applicability, including efforts to address tumor types with historically lower immunogenicity, but these programs are secondary to the RP1 pathway in the near term. [Source overview of pipeline including RP2/RP3]
-
Next steps and considerations: The company has indicated it is evaluating options, including accelerated approval pathways and potential strategic actions, while continuing engagement with the FDA to determine a viable path forward for RP1 in advanced melanoma. [FDA interaction summaries and company statements]
If you’d like, I can pull the latest primary sources (FDA communications, press releases, and conference abstracts) and summarize the exact regulatory language and timelines. I can also provide a quick, investor-oriented snapshot (timeline, key milestones, and current valuation implications) with citations.